Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Genfit

Biotech & Life Sciences · Loos, France · Founded 1999 · IPO 2019 Thoroughbred

Develops drugs for the prevention and treatment of cardiometabolic and neurodegenerative diseases

Valuation
$423M
Market cap · 2026
Revenue
$78M
Latest reported FY
EBITDA
$18M
Latest reported FY

Investors

1 investor on Genfit's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 1 investor entered at this stage
Finorpa

Global footprint

Where Genfit has talent and traffic

AI talent share
1.4% of workforce is AI talent
(3 of 212 staff)
Core AI10.47%
Other AI20.94%
Non-AI workforce20998.58%
Workforce by country
8 countries with
team presence
🇫🇷 France85.9%
🇺🇸 United States7%
🇨🇭 Switzerland2.7%
🇧🇪 Belgium1.9%
🇬🇧 United Kingdom0.6%
Top 5 of 8 shown
Web traffic by country
7.1K monthly visits
across markets
🇫🇷 France54.9%
🇺🇸 United States25.4%
🇮🇳 India18.3%
🇬🇧 United Kingdom1.4%
🇪🇸 Spain1.4%
Top 5 markets shown

Market sentiment

What the market is saying about Genfit

An AI-synthesized read of the highest-engagement posts about Genfit on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Genfit on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.